Edelweiss Mid Cap Fund
The scheme aims to generate long term capital appreciation from a portfolio that is substantially constituted of equity and equity related securities of Mid Cap companies.
Growthvine rating: 5/5 — ranked #2 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹107.54 (as of 2026-11-13) |
|---|
| AUM | ₹19,230 Cr |
|---|
| Expense ratio | 1.42% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Sumanta Khan |
|---|
| Exit load | 1% for redemption within 90 days |
|---|
Performance & risk
| 5-year annualised return | 14.69% |
|---|
| Sharpe ratio | 0.66 |
|---|
| Standard deviation | 18.41% |
|---|
| Max drawdown | −41.14% |
|---|
| Alpha | 3.66 |
|---|
| Beta | 0.97 |
|---|
Over 5 years, captured 96.7% of NIFTY Midcap 150's upside and 88.8% of its downside.
Market cap allocation
| Large cap | 14.0% |
|---|
| Mid cap | 71.0% |
|---|
| Small cap | 15.0% |
|---|
Concentration
| Top 5 holdings | 13.8% |
|---|
| Top 10 holdings | 23.7% |
|---|
| Total holdings | 103 |
|---|
| Index overlap | 53.5% |
|---|
| Active share | 46.5% |
|---|
Top holdings
- Federal Bank Ltd. — 3.5%
- Multi Commodity Exchange of India Ltd — 3.4%
- COFORGE LIMITED — 2.4%
- Persistent Systems Limited — 2.4%
- Clearing Corporation of India Ltd. — 2.3%
- Solar Industries India Limited — 2.1%
- Marico Limited — 2.1%
- Indian Hotels Co. Ltd — 2.0%
- City Union Bank Ltd — 2.0%
- Ipca Laboratories Ltd. — 1.9%
Top sectors
- Banking & Financial — 23.5%
- Automobile — 8.6%
- Pharma & Biotech — 7.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 2.9% | Q3 | #23 of 31 |
| 2025 | 3.8% | Q2 | #11 of 29 |
| 2024 | 38.9% | Q1 (Top) | #4 of 29 |
| 2023 | 38.4% | Q2 | #13 of 28 |
| 2022 | 2.4% | Q2 | #11 of 22 |